Foundation Medicine and AstraZeneca Enter Strategic Collaboration for Lynparza Companion Diagnostic Assay
Lynparza is an innovative, oral PARP inhibitor that exploits
tumor DNA repair pathway deficiencies to preferentially kill cancer
cells. This mode of action gives olaparib the potential for activity in
a range of tumor types with DNA repair deficiencies. Lynparza is
approved in the US for the treatment of patients with germline
BRCA-mutated advanced ovarian cancer and in the
Under the terms of the agreement,
"Following our new master collaboration agreement with AstraZeneca, we
are pleased to launch this first strategic initiative to support and
advance the development of Lynparza in a number of cancers,"
Lynparza (olaparib) is an innovative, first-in-class oral poly ADP-ribose polymerase (PARP) inhibitor that exploits tumour DNA damage response (DDR) pathway deficiencies to preferentially kill cancer cells. Lynparza is the foundation of AstraZeneca's industry-leading portfolio of compounds targeting DNA damage response (DDR) mechanisms in cancer cells. Lynparza is approved in the EU for the treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer. It is approved in the US for the treatment of patients with germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
About AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients' lives and the Company's future. With at least 6 new medicines to be launched between 2014 and 2020 and a broad pipeline of small molecules and biologics in development, we are committed to advance New Oncology as one of AstraZeneca's six Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by our investment in Acerta Pharma in haematology.
By harnessing the power of four scientific platforms -- immuno-oncology, the genetic drivers of cancer and resistance, DNA damage response and antibody drug conjugates -- and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements regarding an agreement between
Foundation Medicine and AstraZeneca to develop a companion diagnostic
assay for Lynparza; the development of a coordinated regulatory strategy
for Lynparza and the companion diagnostic assay; the ability of the
companion diagnostic assay to detect multiple classes of genomic
alterations across a range of genes involved in Homologous Recombination
Repair (HRR) and advance the development of Lynparza in a number of
cancers; and FMI's ability to develop an FDA-approved universal
companion diagnostic assay. All such forward-looking statements are
based on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in or
implied by such forward-looking statements. These risks and
uncertainties include the risk that Foundation Medicine is not able to
develop a companion diagnostic assay that meets the requirements of
AstraZeneca or the
News Provided by Acquire Media